Body Pharm GHK-Cu

UK researchers can buy GHK-Cu copper peptide from this page as a prefilled 50 mg dial-a-dose subcutaneous pen. Each pen comes with a batch-specific Certificate of Analysis, refrigerated 2–8 °C dispatch from a British facility, and clear "for laboratory research only, not for human use" labelling consistent with MHRA's medicinal products framework [3][4].

What separates a 2026 research-grade listing from a cosmetic supplier is verifiable provenance. Every pen we ship is traceable to a synthesis batch, HPLC purity readout, and mass-spec confirmation. The tripeptide GHK (glycyl-L-histidyl-L-lysine) bound to copper(II) is one of the most-cited peptides in dermatological literature. Pickart & Margolina's 2018 review reported modulation of approximately 4,000 human genes in cultured cells [14]. Below, I've broken down what "research grade" actually means in UK supply terms, and where the published evidence ends.

What you'll learn: the chemical identity and endogenous role of GHK-Cu; the current state of mechanistic evidence and its limitations; what "research grade" means in UK regulatory and quality terms; how Body Pharm's batch traceability works; and how to interpret dosing protocols from published animal studies.

Key Takeaways

• GHK-Cu is a naturally occurring tripeptide-copper complex with documented roles in collagen synthesis and gene expression, but human RCT evidence remains absent as of 2026
• The Body Pharm pen is prefilled (50 mg of GHK-Cu in a 3 mL cartridge) and dials the dose directly in milligrams — no reconstitution, no bacteriostatic water, no draw-up volume
• Research-grade GHK-Cu must include HPLC purity ≥98%, mass-spectrometry identity confirmation, and bacterial endotoxin (LAL) testing in EU/mg
• Body Pharm supplies each pen with full per-lot traceability, including HPLC chromatogram, MS identity file and endotoxin result on request
• UK delivery is free and tracked; unopened pens can be returned within 14 days if the seal remains intact

What Is GHK-Cu? A Plain-English Summary

GHK-Cu is glycyl-L-histidyl-L-lysine bound to copper(II), a naturally occurring tripeptide-copper complex with a molecular weight of 340.38 g/mol. Loren Pickart first isolated it from human plasma in 1973 [14]. It circulates endogenously in plasma, saliva, and urine, where it works as a signalling molecule rather than a structural protein fragment.

According to Pickart & Margolina's 2018 review, plasma GHK concentrations fall from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60 [14]. This decline is frequently cited as the rationale for exogenous supplementation in research models. Independent post-2022 replication of those plasma figures remains thin in the published literature. Treat the age-decline numbers as historical reference points rather than current clinical benchmarks, no recent peer-reviewed studies have confirmed them [14].

The injectable research-grade pen sold here is chemically distinct in purpose from the "copper peptides" marketed in cosmetic serums. Topical formulations are dermal-delivery products designed for skin application. The pen format on this page is intended for in-vitro and animal research workflows, including subcutaneous injection studies covered in our GHK-Cu dosing protocol guide.

Research Use Only. Supplied for laboratory research. Not for human or veterinary use, not a medicine, and not for cosmetic application [12][13].

GHK-Cu Research Mechanisms: What Studies Show

Four mechanistic threads dominate the GHK-Cu literature: extracellular matrix synthesis, broad gene-expression modulation, wound-healing signalling via TGF-β (Transforming Growth Factor-beta) and MMP (Matrix Metalloproteinase) pathways, and neuroprotection in rodent models. The majority of this evidence comes from in vitro fibroblast cultures and animal work. As of 2026, no peer-reviewed human RCT (Randomised Controlled Trial) has tested subcutaneous GHK-Cu administration [6][8].

The approximately 4,000-gene figure is the headline quantitative claim and originates from Pickart & Margolina's 2018 work. No 2024–2026 multi-omics replication has updated it. Treat it as historical in vitro data rather than in-human evidence, the original study used cultured cells, not human subjects [14][15].

Much of the wound-healing mechanistic literature predates 2023 and was generated in topical or cell-culture contexts. This limits direct translation to subcutaneous research protocols, because the delivery route and tissue environment differ substantially [6][7]. Researchers planning injection studies should recognise that mechanism and route are decoupled in the current evidence base. The pathways are well-described in vitro, but the pharmacokinetics of subcutaneous delivery in humans are not. Study design should reflect that gap. Our GHK-Cu dosing protocol summarises the rodent-derived dose ranges typically used. The BPC-157 vs TB-500 comparison covers how GHK-Cu sits alongside other recovery-focused research peptides.

What Does 'Research Grade' Actually Mean?

Research-grade GHK-Cu is peptide tested to ≥98% HPLC purity. Identity is confirmed by mass spectrometry. It is assayed for endotoxin by LAL (Limulus Amebocyte Lysate, typically ≤1 EU/mg) and supplied with a per-lot Certificate of Analysis. It sits between cosmetic-grade (formulated for topical use, often 1% in a serum base with no parenteral endotoxin spec) and pharmaceutical-grade (a licensed medicinal product manufactured under full UK GMP per the Human Medicines Regulations 2012).

The practical difference matters for injection studies. A cosmetic 1% GHK-Cu serum will publish a purity figure on its CoA (Certificate of Analysis) but no endotoxin limit relevant to parenteral use, since it was never intended for that route [4]. A research-grade product, by contrast, should declare bacterial endotoxin in EU/mg. UK suppliers are not obliged to meet the EP (European Pharmacopoeia)/USP (United States Pharmacopeia) parenteral threshold of ≤0.25 EU/mL that applies to licensed sterile products [4].

What a credible Certificate of Analysis contains

A research-grade CoA should list:

• Lot number
• Synthesis date
• Peptide content and net peptide weight
• HPLC purity percentage with chromatogram
• Identity confirmation (MS or MS/MS)
• Bacterial endotoxin result in EU/mg by LAL
• Residual solvents where relevant
• Appearance and storage conditions

Many UK research peptide vendors publish purity and identity but omit an explicit EU/mg endotoxin figure. Endotoxin testing adds cost, and that is the single most common gap in supplier documentation [3].

UK laboratory standards in plain terms

Post-Brexit, UK research peptide labs are not bound by EU directives directly. Reputable suppliers align voluntarily with ICH Q7 (International Council for Harmonisation guideline for GMP of active pharmaceutical ingredients) and ISO 9001 quality systems, with analytical methods referenced to European or US Pharmacopoeia monographs.

Body Pharm operates EU-standard batch validation with full per-lot traceability. Every pen links back to a synthesis record, HPLC trace, MS identity file and LAL result you can request before purchase. The matching GHK-Cu dosing protocol sets out how to apply that material in subcutaneous study designs.

Body Pharm GHK-Cu: Batch Traceability & Quality

Body Pharm GHK-Cu is filled, sealed and dose-validated to EU laboratory standard. Each batch ships under full traceability documentation. A per-lot Certificate of Analysis is available on request (Body Pharm UK, 2026). The product is supplied as a prefilled, sealed pharmaceutical-grade dial-a-dose pen (50 mg of GHK-Cu in a 3 mL cartridge), labelled with lot number, fill weight and synthesis date. Every unit links back to its production record.

Quality control follows ICH Q7-aligned API (Active Pharmaceutical Ingredient) practice rather than cosmetic-tier QC. HPLC purity, mass-spectrometry identity confirmation and a bacterial endotoxin (LAL) result are recorded against the specific lot you receive.

Many UK research vendors publish purity figures but omit explicit endotoxin data on the public listing [1][3]. Body Pharm makes the EU/mg LAL figure available on the lot CoA. Buyers planning subcutaneous injection studies can verify it against their own protocol thresholds before purchase.

Status is research use only, not for human or veterinary administration, consistent with the regulatory position UK research peptide suppliers operate under post-Brexit [12][13]. Researchers verifying provenance should request the CoA quoting the lot number printed on the pen. The document returned should include HPLC chromatogram, MS identity file, LAL result and storage conditions. For applied study design once material is in hand, the GHK-Cu dosing protocol sets out how to dial the dose in milligrams for subcutaneous work.

Methodology & quality box

• Synthesis & fill: EU laboratory standard, prefilled sealed pen, dose-validated per unit
• Identity: HPLC purity + MS confirmation, per lot
• Endotoxin: LAL result in EU/mg on lot CoA
• Traceability: lot number on pen maps to synthesis record, analytical files and shipping batch
• CoA access: issued per lot, available on request before dispatch
• Status: research use only; not a licensed medicinal product

UK Delivery, Packaging & Returns

Orders ship free across the UK via tracked Royal Mail. Most addresses receive delivery within 1–3 working days from dispatch (Body Pharm UK, 2026). Tracking is emailed on the day the parcel leaves the facility, so you can plan cold-chain handling and have 2–8 °C storage ready on arrival.

Dispatch is discreet by default. Parcels go out in plain, unbranded outer packaging with no product names, peptide references or laboratory markings on the label, a concern UK research buyers routinely raise when ordering to home or shared institutional addresses.

Returns window

Unopened, unused pens can be returned within 14 days of delivery for a refund. The tamper-evident seal must be intact and storage conditions must have been maintained. Opened or used pens cannot be returned for sterility and traceability reasons, once the seal is broken, the product's integrity cannot be verified. If a lot fails your incoming QC against the CoA, contact us before opening further units.

GHK-Cu Dosing Protocols for Research

The Body Pharm pen is prefilled and dials the dose directly in milligrams — there is no powder, no bacteriostatic water and no draw-up volume. Practitioner subcutaneous protocols cluster at 0.5–2 mg/day depending on the research endpoint, and the pen's dial covers that range directly. Published animal studies most commonly reference subcutaneous GHK-Cu at 1–10 mg/kg; that route dominates rodent wound-healing and tissue-repair literature because subcutaneous injection allows controlled systemic exposure [5]. Human evidence remains confined to topical cosmetic work, including a 12-week trial in 71 women using formulations in the 0.1–1% concentration range applied to skin [4].

Topical percentages are not interchangeable with injectable mg figures. The delivery route, absorption kinetics and tissue distribution differ fundamentally. No peer-reviewed human RCT has yet validated a subcutaneous dose in people as of 2026 [4][5].

For protocol design, anchor the dosing range you select to a specific cited study matching your model. Aggregating from secondary sources makes your dose rationale harder to defend to ethics committees and reviewers. Because the pen dials the dose in milligrams, there is no reconstitution arithmetic to compound errors across a study arm. Our full GHK-Cu dosing protocol walks through the endpoint-mapped dose ranges and how to set them on the dial.

This section summarises published research parameters for context only. It is not medical advice, not a recommendation for human administration, and not a substitute for ethics-approved protocol review at your institution.

GHK-Cu vs Other Skin & Recovery Peptides

GHK-Cu differs from other recovery peptides primarily in its copper-mediated collagen synthesis and broad gene-expression modulation. BPC-157, TB-500 and NAD+ act through unrelated pathways targeting different cellular systems [2][14]. Researchers selecting a compound for a specific endpoint should match mechanism to model rather than treating these peptides as interchangeable.

The mechanistic overlap with NAD+ is limited to broad gene-expression effects. GHK-Cu operates through copper-dependent signalling; NAD+ is a mitochondrial cofactor. The pathways are distinct. For a deeper comparison of the two most common recovery comparators, see our BPC-157 vs TB-500 comparison. Revisit the GHK-Cu dosing protocol once you've selected the compound that matches your endpoint.

Frequently Asked Questions

Is GHK-Cu legal to buy in the UK?

GHK-Cu is legal to buy in the UK for research purposes. The tripeptide is not a scheduled substance under the Misuse of Drugs Act 1971. The MHRA has not issued peptide-specific guidance between 2024 and 2026 that would change this position [unverified]. UK suppliers, including Body Pharm, sell GHK-Cu under standard "for laboratory research only, not for human use" disclaimers to remain outside the medicinal products regime [2][4].

Do I need to reconstitute the GHK-Cu pen?

No. The Body Pharm pen is prefilled and dials the dose in milligrams. There is no powder, no bacteriostatic water, and no draw-up volume to calculate.

How should GHK-Cu be stored?

Store the prefilled pen at 2–8 °C, protected from light, and never freeze it. Unopened shelf life is 24 months. Once the pen is first pierced (first use), use it within 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days. Freeze-thaw cycles precipitate the copper-peptide complex and degrade the peptide [10][13].

What dose does the pen deliver?

The pen dials the dose directly in milligrams across the 0.5–2 mg/day range used in practitioner subcutaneous protocols. Endpoint-mapped ranges and how to set them on the dial are in the GHK-Cu dosing protocol.

Can I return an opened pen?

No. Only unopened items in their original packaging are eligible for return within 14 days of delivery. Once the seal is broken, chain-of-custody and sterility cannot be verified.

Does Body Pharm ship outside the UK?

Body Pharm currently dispatches to UK addresses only. International availability and customs handling for research peptides vary by jurisdiction and are not confirmed for 2026.

Next Steps

Request the Certificate of Analysis for your intended lot before purchase by quoting the batch number. Verify the HPLC purity, MS identity and EU/mg endotoxin result against your protocol thresholds. Once the pen arrives, transfer immediately to 2–8 °C storage and consult the GHK-Cu dosing protocol for the endpoint-mapped dose ranges to dial for your study design.

References

1. UK research-peptide vendor documentation and Certificate-of-Analysis practice (purity, endotoxin, traceability). [unverified — no linkable source]
2. General GHK-Cu vs recovery-peptide mechanism comparisons and UK legal-status commentary. [unverified — no linkable source]
3. UK laboratory quality and MHRA medicinal-products framework context (ICH Q7 / ISO 9001 alignment). Regulatory/quality context, not a study. [unverified — no linkable source]
4. Cosmetic vs research-grade / parenteral endotoxin and topical-formulation dosing context (0.1–1% cosmetic trials). [unverified — no linkable source]
5. Published animal subcutaneous GHK-Cu dosing (1–10 mg/kg) cited in rodent wound-healing literature. [unverified — no linkable source]
6. Dermatica review of GHK-Cu evidence (collagen, TGF-β/MMP, 12-week topical cosmetic trial). Secondary explainer. [unverified — no linkable source]
7. Wikipedia GHK-Cu overview (wound-healing and neuroprotective signalling context). Tertiary source. [unverified — no linkable source]
8. Clinician commentary and standard peptide storage practice. [unverified — no linkable source]
9. General peptide storage and handling practice guidance. [unverified — no linkable source]
10. Vendor-assigned expiry and temperature-stability handling conventions for peptide pens. [unverified — no linkable source]
11. Prefilled-pen in-use and handling conventions for copper-peptide solutions. [unverified — no linkable source]
12. Research-use-only labelling and status conventions for UK unlicensed research reagents. [unverified — no linkable source]
13. UK regulatory position (MHRA; not-for-human-use disclaimers post-Brexit). Regulatory context, not a study. [unverified — no linkable source]
14. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. pubmed.ncbi.nlm.nih.gov/29986520
15. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. pubmed.ncbi.nlm.nih.gov/18644225